Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Gastric acid secretion inhibitor
Original Date: 
December 2008
Revised Date: 
November 2012
  • Treatment of reflux esophagitis
  • PO
    • Bolus feeds: administer 30 minutes before feeds
  • < 28 days of age: 0.5 - 1.0 mg/kg/day once daily or divided Q12H
  • > 28 days of age: 1.0 - 2.0 mg/kg/day once daily or divided Q12H
Side Effects: 
  • Dermatologic: rash
  • GI: hypergastrinemia, diarrhea
  • Hematologic: rare
  • Hepatic: elevated serum transaminases
  • Renal: proteinuria
Parameters to Monitor: 
  • CBC
  • Liver function , liver enzymes
  • Renal function
Reconstitution and Stability: 





-Zhang W, Kukulka M, Witt G et al. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Pardiatr Drugs.2008; 10(4): 265-74.

-Lau E. (Editor). Drug Handbook and Formulary- The Hospital for Sick Children. Toronto: 2009-2010.

-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 16th Edition. Hudson: Lexi-Comp Inc.; 2009.

-Young TE, Mangum B. Neofax®. 20th edition. Raleigh: Acorn Publishing; 2007.


The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.